FROM

For people living with chronic migraine, life was defined by pain, unpredictability, and stigma. Despite debilitating symptoms and lost productivity, migraine was often misunderstood — and treatments were limited to repurposed drugs with poor tolerability, forcing many patients to discontinue therapy or overuse acute medications. Communication between neurologists and patients was often strained by frustration and lack of viable options.

TO

Aimovig (erenumab), the first CGRP therapy for migraine prevention, brought renewed hope to patients and their families. The agency team helped shape the strategic and creative foundation for a highly successful, award-winning launch — starting with a disease awareness platform that reframed migraine as a serious, biologically-driven condition. The final concept grounded in loss and disruption sparked empathy, urgency, and belief in a new path forward — offering patients the chance to reclaim time, dignity, and daily life.